• Ishaq Lat, Scott Micek, Jeffrey Janzen, Henry Cohen, Keith Olsen, and Curtis Haas.
• University of Chicago Medical Center, Chicago, IL 60637, USA.
• J Crit Care. 2011 Feb 1;26(1):89-94.

PurposeThis study evaluated the use of off-label medications in the intensive care unit (ICU) setting and their varying levels of evidence.Materials And MethodsThirty-seven ICUs from 24 US sites participated in this prospective, multicenter, observational study during a single 24-hour period. All medication orders were evaluated for Food and Drug Administration-labeled indications, strength of evidence, and strength of recommendation. Off-label medication orders were evaluated for indication, dose, route of administration, duration of therapy, and whether they were supported by institutional guidelines.ResultsA total of 414 patients were enrolled, yielding 5237 medication orders for analysis. Of these, 1897 orders (36.2%) were off-label. The 3 drug classes that accounted for the most off-label orders were bronchorespiratory, gastrointestinal, and immunology. The majority of off-label medication orders (89.1%) were initiated after patient admission to the ICU. Nine hundred twenty-eight (48.3%) of the off-label medication orders had grade C or no evidence.ConclusionsThe use of off-label medication therapies in the US adult critical care units is common, a majority of which are initiated after admission to the ICU and a significant portion of which are supported with inferior levels of evidence.Copyright © 2011 Elsevier Inc. All rights reserved.

16 keywords...

hide…